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ABSTRACT  
 
Phosphatidylinositol-3-kinase (PI3K)/AKT pathway aberrations are common 
in cancer. By applying mass spectroscopy-based sequencing and reverse 
phase protein arrays to 547 human breast cancers and 41 cell lines, we 
determined the subtype specificity and signaling effects of PIK3CA, AKT 
and PTEN mutations, and the effects of PIK3CA mutations on 
responsiveness to PI3K inhibition in-vitro and on outcome after adjuvant 
tamoxifen. PIK3CA mutations were more common in hormone receptor-
positive (33.8%) and HER2-positive (24.6%) than in basal-like tumors 
(8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone 
receptor-positive cancers with PTEN protein levels also being significantly 
lower in hormone receptor-positive cancers. Unlike AKT1 mutations, 
PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines 
than tumors, suggesting a selection for these but not AKT1 mutations 
during adaptation to culture. PIK3CA mutations did not have a significant 
impact on outcome in 166 hormone receptor-positive breast cancer 
patients after adjuvant tamoxifen. PIK3CA mutations, in comparison with 
PTEN loss and AKT1 mutations, were associated with significantly less and 
indeed inconsistent activation of AKT and of downstream PI3K/AKT 
signaling in tumors and cell lines, and PTEN loss and PIK3CA mutation 
were frequently concordant, suggesting different contributions to 
pathophysiology. PTEN loss but not PIK3CA mutations rendered cells 
3
sensitive to growth inhibition by the PI3K inhibitor LY294002. Thus, PI3K 
pathway aberrations likely play a distinct role in the pathogenesis of 
different breast cancer subtypes. The specific aberration may have 
implications for the selection of PI3K-targeted therapies in hormone 
receptor-positive breast cancer.  
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The phosphatidylinositol-3-kinase (PI3K) pathway mediates key cellular functions 
including growth, proliferation, survival, angiogenesis and motility.1 PI3K 
phosphorylates membrane phosphatidylinositols, thereby recruiting AKT and 
phosphoinositide-dependent kinase (PDK) 1 to the cell membrane. PDK1 and 
PDK2, likely the TORC2 complex, phosphorylate AKT and initiate a downstream 
signaling cascade. The tumor suppressor PTEN reverses the effects of PI3K by 
dephosphorylating the same site on membrane phosphatidylinositols that is 
phosphorylated by PI3K. The growth factor receptor signaling and energy 
sensing LKB1-AMPK pathways integrate at the tuberous sclerosis complex 
(TSC) resulting in information transfer to the TORC1 complex and protein 
synthesis. In normal cells, the PI3K pathway is under tight homeostatic control 
through feedback regulatory loops that maintain normal cellular function and 
regulate glucose homeostasis.2  
 
Activating mutations in PIK3CA, PIK3R1, and AKT1 and inactivating mutations in 
PTEN, LKB1 and TSC2 are present in a broad range of tumor types.1 Further, 
germline mutations in PTEN, LKB1, and TSC result in hamatomatous cancer 
predisposition syndromes (Cowdens, Peutz Jaeghers, and tuberous sclerosis, 
respectively). Additional pathway components including PIK3CA, PIK3CB, AKT1 
and AKT2, PDK1, p70S6 Kinase (p70S6K) and IKBKE are frequently amplified in 
tumors.1 Since genomic aberrations can predict responsiveness to targeted 
 
therapies, and since multiple PI3K pathway members are frequently aberrant in 
breast tumors, targeting this pathway may provide a highly effective therapeutic 
approach.1,3   
 
PIK3CA mutations, primarily at hot spots in exons 9 and 20 that encode portions 
of the helical and kinase domains of PI3K, occur in approximately one-third of 
breast cancers.4 These mutations have been reported to activate AKT and 
downstream signaling in model systems but their effects in patient tumors are 
unknown.5 PTEN mutations are relatively uncommon in breast cancer (<5%); 
however, PTEN protein loss (e.g. promoter methylation, loss of heterozygosity 
and regulation at the RNA or protein level) is more common (approximately 
30%).1 A recent report identified a somatic mutation in the PH domain of AKT1 
(E17K) in 8% of breast cancers in a small sample set.6 This mutation activates 
AKT1 by recruiting it to the membrane through a PI3K-independent mechanism.6 
However, two large-scale sequencing studies failed to detect mutations at this 
site in any AKT isoform across multiple tumor types, raising the possibility that 
the former study overestimated the frequency of AKT1 mutations in breast 
cancer.7,8 Although the frequencies of these mutations have been explored in 
small breast cancer sets, there has been no comprehensive analysis of the 
mutational frequency of multiple PI3K pathway members in a large breast cancer 
series representing the three major subtypes of hormone receptor-positive, 
HER2-positive and basal-like tumors. As the cell of origin, treatment, and 
outcomes are markedly different in the three major breast cancer subtypes, it is 
 
critical that the effects of PI3K pathway aberrations on pathophysiology and 
therapy responsiveness are analyzed independently in each subtype. Recent 
studies from us and others implicate PIK3CA mutations and PTEN loss in 
resistance of HER2-positive breast cancers to trastuzumab.9,10 However, the role 
of PI3K pathway aberrations in the clinical behavior and therapy responsiveness 
of hormone receptor-positive tumors remains controversial, in part due to 
analysis of small and clinically heterogeneous sample sets.  
 
We thus determined the frequency, breast cancer subtype specificity and 
signaling effects of PIK3CA, AKT and PTEN mutations in 547 well-characterized 
human breast tumors and 41 breast cancer cell lines. Using 166 uniformly 
treated early stage hormone receptor-positive tumors from a single center, we 
examined the effects of common PIK3CA mutational aberrations on patient 
outcomes after adjuvant tamoxifen. 
  
Materials and Methods 
 
Human Breast Tumor Samples 
Five hundred and forty-seven frozen human breast tumors were obtained from 
Tumor Banks following pathologist review under the auspices of Institutional 
Review Board (IRB)-approved protocols at Clinic Hospital (Valencia, Spain-306 
tumors), the Netherlands Cancer Institute (NKI-34 tumors) and the M. D. 
Anderson Cancer Center (MDACC). Tumors were collected and frozen in liquid 
 
nitrogen within one hour of surgical excision after review of the tumor and a 
frozen section by a pathologist. Tumors were characterized for estrogen receptor 
alpha (ER) and progesterone receptor (PR) status by immunohistochemistry 
(IHC) or ligand-binding dextran-coated charcoal assay. ER/PR positivity was 
designated when nuclear staining occurred in ≥10% of tumor cells or with ligand 
binding of ≥10 fmol/mg. Hormone receptor positivity was designated when ER 
and/or PR were positive. HER2 status was assessed by IHC and/or fluorescent 
in situ hybridization (FISH). HER2 positivity was designated when 3+ 
membranous staining occurred in ≥10% of tumor cells or with a HER2/CEP17 
ratio of >2.0. Tumors were designated as basal-like (i.e. triple receptor-negative) 
when they were negative for HER2, ER and PR expression. Frozen tissue was 
used for DNA (Table 1) and protein extraction. DNA and protein from breast 
cancer cell lines (supplemental table 1) was obtained from Lawrence Berkeley 
National Laboratory (LBNL) at University of California San Francisco (UCSF). 
 
Mass spectroscopy-based approach evaluating single nucleotide 
polymorphisms 
A mass spectroscopy-based approach evaluating single nucleotide 
polymorphisms (SNP) was used to detect the E17K-AKT1 mutation, mutations in 
the equivalent sites of AKT2 and AKT3 and 23 known mutations in PIK3CA 
(PIK3CA_A1046V, PIK3CA_C420R, PIK3CA_E110K, PIK3CA_E418K, PIK3CA_E453K, 
PIK3CA_E542K, PIK3CA_E545K, PIK3CA_F909L, PIK3CA_G1049R, 
PIK3CA_G451L456_V, PIK3CA_H1047L, PIK3CA_H1047R, PIK3CA_H1047Y, 
PIK3CA_H701P, PIK3CA_K111N, PIK3CA_M1043V, PIK3CA_N345K, PIK3CA_P539R, 
 
PIK3CA_Q060K, PIK3CA_Q546E, PIK3CA_R088Q, PIK3CA_S405F and 
PIK3CA_T1025S).11,12 Polymerase chain reaction (PCR) and extension primers for 
AKT and PIK3CA were designed using Sequenom, Inc. (San Diego, CA) Assay 
Design. PCR-amplified DNA was cleaned using EXO-SAP (Sequenom), primer 
extended by IPLEX chemistry, desalted using Clean Resin (Sequenom) and 
spotted onto Spectrochip matrix chips using a nanodispenser (Samsung). Chips 
were run in duplicate on a Sequenom MassArray MALDI-TOF MassArray 
system. Sequenom Typer Software and visual inspection were used to interpret 
mass spectra. Reactions where more than 15% of the resultant mass ran in the 
mutant site in both reactions were scored as positive. E17K-AKT1 mutations 
were specifically confirmed with independent primers. All mutations were 
confirmed by Sanger sequencing in the MDACC CCSG-supported sequencing 
core. Results were concordant in all cases. 
 
PTEN Sequencing 
A high-throughput approach to the resequencing of PTEN and PIK3CA was 
performed on 88 breast cancers following whole genome amplification.  The 
resequencing protocol was as follows: oligonucleotide primers (sequences 
available upon request) for amplifying the gene coding exons were designed to 
give a product size in the range of 200–700 base pairs (bp) with a minimum of 40 
bp flanking the splice sites using the Exon Primer program, which is bundled with 
the UCSC Genome Browser (build hg17). M13F and M13R tags were added to 
the forward and reverse primers, respectively. Five nanograms of genomic DNA 
from each breast tumor were amplified in an 8-
13
l PCR reaction using AmpliTaq 
 
Gold (Applied Biosystems, Foster City, CA) on PE 9700 machines and 
subsequently cleaned using a diluted version of the EXO-SAP-based PCR 
product pre-sequencing kit (USB Corporation, Cleveland, OH) dispensed by a 
nanoliter dispenser (Deerac Fluidics Equator, Inc., Cambridge, MA). All PCR set-
up procedures were performed in a 384-well format using a Biomek FX 
(Fullerton, CA) workstation after optimization. Sequencing reactions were then 
performed using the M13 primers along with BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, Foster City, CA) and cleaned with BET 
before separation on an ABI 3730xl DNA Analyzer. Base calling, quality 
assessment and assembly were carried out using the Phred, Phrap, Polyphred, 
Consed software suite. All sequence variants identified were verified by manual 
inspection of the chromatograms. Mutation frequencies determined using this 
approach should be considered lower estimates as all exon sequences were not 
covered in all subjects with perfect mutation capture. In contrast, the false-
positive rate with this approach is low to non-existent.13
 
Reverse Phase Protein Lysate Microarray (RPPA) 
RPPA as performed in our laboratory has been described previously14,15 and was 
used to quantify PTEN expression, and phosphorylation of AKT at threonine 308 
and serine 473, glycogen synthase kinase (GSK) 3 at serine 21, mammalian 
target of rapamycin (mTor) at serine 2448 and p70S6 kinase (p70S6K) at 
threonine 389 as a ratio to total expression of each protein using antibodies from 
Cell Signaling, Inc. (Danvers, MA), Epitomics, Inc. (Burlingame, CA-total p70S6K 
 
antibody) and Santa Cruz (Santa Cruz, CA-total GSK3 antibody). Because of 
potential effects of differences in tissue handling on protein phosphorylation in 
particular, only tumors from the largest single institution batch (i.e. from Clinic 
Hospital) were used for this analysis.    
 
Cell Lines 
Twelve hormone receptor-positive breast cancer cell lines were cultured in 
complete medium (RPMI1640 supplemented with 5% fetal bovine serum (FBS)) 
and treated with LY294002 to determine the concentration resulting in 50% 
growth inhibition (GI50) in each cell line. 
 
Statistical Analysis 
Group characteristics were tabulated and compared between groups with the chi-
square test or Kruskal-Wallis test as appropriate. One hundred and sixty-six 
hormone receptor-positive breast cancers from patients treated with adjuvant 
tamoxifen were used for the outcomes analyses. Overall survival (OS) was 
measured from the date of diagnosis to the date of death from any cause.  
Recurrence-free survival (RFS) was measured from the date of diagnosis to the 
date of breast cancer recurrence. Patients who died before experiencing a 
disease recurrence were considered censored at their date of death. Survival 
outcomes were estimated with the Kaplan-Meier method and compared between 
groups with the log-rank statistic. Multivariable Cox proportional hazards models 
 
were fit to determine the association of PIK3CA mutations with survival outcomes 
after adjustment for other patient characteristics.  
 
Results 
Frequency of PIK3CA, AKT and PTEN mutations in different breast cancer 
subtypes.   
A mass spectroscopy-based approach using methods designed to detect single 
nucleotide polymorphisms (SNP)11,12 was used to detect the E17K-AKT1 
mutation, mutations in the equivalent sites of AKT2 and AKT3 and mutations in 
PIK3CA in 547 breast cancers, primarily from Caucasian and Hispanic patients, 
and 41 cell lines (Table 1). This approach is more sensitive than conventional 
Sanger sequencing, having the potential to detect mutations that are present in 
only a subset of tumor cells or in tumors with high levels of normal cell 
contamination, which is commonly the case in breast cancer.11,12 The E17K-
AKT1 mutation (Figure 1) was detected in only 6 of 418 breast cancers (1.4%). 
An additional two tumors returned equivocal results due to potential E17K-AKT1 
mutation peaks comprising less than 15% of the area of the wild-type peak that 
could represent possible mutations. Nevertheless, while this confirms the likely 
role of E17K-AKT1 mutations in breast cancer pathophysiology, the frequency is 
significantly lower than the 8% previously reported in a set of 55 breast cancers.6 
E17K-AKT1 mutations were restricted to hormone receptor-positive breast 
cancers expressing both ER and PR (6/190, 3.2%). No E17K-AKT1 mutations 
were detected in 65 HER2-positive or 113 hormone receptor- and HER2-
 
negative (triple receptor-negative or basal-like) breast cancers. E17K-AKT2 and 
–AKT3 mutations were not detected in any sample suggesting that they do not 
contribute to breast cancer pathophysiology.  
 
PIK3CA mutations were detected in 117/547 breast cancers (21.4%), 
significantly more frequently than AKT1-E17K mutations (p=0.00001). Of the 23 
sites in PIK3CA that were assessed, mutations were detected in exon 20 that 
encodes the catalytic domain of PI3K (68 PIK3CA_H1047R, 2 PIK3CA_H1047L, 2 
PIK3CA_H1047Y and 1 PIK3CA_G1049R), in exon 9 that encodes the PI3K helical 
domain (31 PIK3CA_E545K and 6 PIK3CA_E542K) and at other sites (4 
PIK3CA_N345K, 2 PIK3CA_E418K and 1 PIK3CA_K111N). Four hormone receptor-
positive breast cancers possessed two distinct PIK3CA mutations 
(PIK3CA_H1047R with PIK3CA_E545K, PIK3CA_H1047Y with PIK3CA_E545K, 
PIK3CA_H1047R with PIK3CA_K111N, PIK3CA_E545K_with PIK3CA_E418K). 
Although E17K-AKT1 mutations were restricted to hormone receptor-positive 
breast cancers, PIK3CA mutations were present in all breast cancer subtypes. 
However, PIK3CA mutations were more frequent in hormone receptor-positive 
(33.8%, p=0.00001) and HER2-positive tumors (24.6%, p=0.0007) than triple 
receptor-negative or basal-like breast cancers (8.3%). There was no difference in 
the frequency of PIK3CA mutations between ER-positive and –negative/HER2-
positive tumors (9/29 vs. 7/35, p=0.39). PTEN mutations were assessed in a 
subset of 88 patients by Sanger sequencing with only two mutations being found, 
both in hormone receptor-positive tumors. Concordant with the subtype 
 
specificity of mutations, mean PTEN protein levels assessed by RPPA were also 
significantly lower among hormone receptor-positive tumors (Table 1).   
 
Unlike E17K-AKT1 mutations that were not detected in 41 breast cancer cell 
lines (supplemental table 1), PIK3CA (16/41, 39%) and PTEN mutations (8/41, 
20%) (http://www.sanger.ac.uk) were more common in cell lines than patient 
tumors (Table 1). E17K-AKT1, PIK3CA, and PTEN (where assessed) mutations 
were mutually exclusive in all patient tumors and breast cancer cell lines 
assessed.  
 
Effect of aberrations in the PI3K pathway on PI3K pathway activation in 
hormone receptor-positive breast cancer 
PTEN loss is well known to activate the core PI3K signaling pathway but the 
functional proteomic effects of PIK3CA mutations in human tumors are not well 
characterized. We thus applied RPPA to determine if PTEN loss and PIK3CA 
mutations have similar effects on PI3K pathway signaling in human hormone 
receptor-positive breast tumors. The tumors were split into two groups (‘PTEN 
low’ and ‘PTEN high’) using the median PTEN protein expression value. As 
expected, AKT phosphorylation at threonine 308 and serine 473 were both 
present at significantly higher levels in ‘PTEN low’ as compared with ‘PTEN high’ 
breast cancers (p=1.7 x 10-16 and 7.9 x 10-15, respectively), as were 
phosphorylation of mTor (p=0.0008) and p70S6K (p=3.6 x 10-15). As indicated in 
figure 2, almost all tumors with high levels of phosphorylation of both threonine 
 
308 and serine 473 in AKT had low PTEN levels. In contrast, there were no 
significant differences in PTEN levels, phosphorylation of AKT, GSK3, mTOR or 
p70S6K between PIK3CA mutant tumors, whether analyzed together or 
separately as catalytic and helical domain mutants, and PIK3CA wild type 
hormone receptor-positive human breast tumors. To exclude the possibility of 
PTEN loss obscuring the effects of PIK3CA mutation on AKT and PI3K pathway 
activation, 153 human hormone receptor-positive breast cancers with PTEN 
protein levels below the median were removed and the analysis repeated with 
high PTEN tumors. However, no significant association was demonstrated 
between PIK3CA mutation or mutation subtype and phosphorylation of AKT, 
GSK3, mTor or p70S6K in the subsequent analysis (data not shown). In contrast, 
AKT phosphorylation was increased in the three AKT1-mutant tumors in this set 
(Figure 2) despite two of these mutant tumors having high PTEN levels. Thus, 
despite the clear association between protein PTEN levels and PI3K pathway 
activation, no clear association was present between PIK3CA mutation (or 
mutation subtype) and PI3K pathway activation in either human tumors (Figure 2) 
or breast cancer cell lines (Figure 3). Thus, PTEN protein loss and PIK3CA 
mutations have markedly different functional effects on the PI3K pathway in 
breast cancer. 
 
PTEN but not PIK3CA mutations render cells sensitive to growth inhibition 
by the PI3K inhibitor LY294002  
 
The distinct functional proteomic effects of PIK3CA mutations and PTEN loss in 
hormone receptor-positive breast cancer suggest that these events may be 
associated with differential sensitivity to PI3K pathway-targeted therapies. 
Indeed, a low level of PTEN protein represented a major determinant of the 
sensitivity of twelve hormone receptor-positive breast cancer cell lines to the 
small molecule PI3K inhibitor LY294002 (Figure 4). In comparison to PTEN loss, 
PIK3CA mutations were associated with relative resistance to LY294002. 
 
Correlation of PIK3CA mutations with outcomes in tamoxifen-treated 
hormone receptor-positive breast cancer patients 
Both the breast cancer subtype and the method of patient treatment influence the 
outcome of patients, rendering it important to determine the effects of aberrations 
in the PI3K pathway on patient outcomes in well characterized tumor subtypes 
with consistent treatment approaches. It has previously been reported that PTEN 
loss is associated with adverse outcomes in breast cancer.9,10,16 A recent study 
by us demonstrated that PIK3CA mutations predict adverse outcomes after 
treatment with trastuzumab for HER2-positive breast cancer.10 There are 
currently insufficient PIK3CA mutations in basal tumors to perform a 
comprehensive analysis (Table 1). We were able to identify a sample set of 166 
early stage hormone receptor-positive tumors from patients treated solely with 
adjuvant tamoxifen. AKT and PTEN mutation status were not included in the 
outcomes analyses due to the low frequency of these aberrations. 
 
 
PIK3CA mutation status was not significantly associated with any measured 
clinical variable (Supplemental Table 2) nor was it significantly associated with 
differential overall survival (OS) or recurrence-free survival (RFS) times in the 
166 patients with early stage tamoxifen-treated hormone receptor-positive breast 
cancer (Figure 5 and Supplemental Table 3). The specific PIK3CA mutation type 
(kinase domain versus all other (largely helical domain)) was also not 
significantly associated with differential patient outcomes (Figure 5 and 
Supplemental Table 3). In multivariable models in the 166 tumors including 
PIK3CA mutation status, age and stage at diagnosis, age at diagnosis (as a 
continuous variable) and stage (II/III vs. I) were found to be significant predictors 
of OS, and only stage at diagnosis was found to be a significant predictor of RFS. 
Tumor grade was not included in the multivariable models due to missing data 
(see Supplemental Table 2). 
 
Discussion 
We have shown that PI3K pathway aberrations are very common in breast 
cancer pointing to a critical role for this signaling pathway in breast 
carcinogenesis. PIK3CA oncogene mutations are particularly common, while 
AKT and PTEN mutations occur less frequently (Table 1). The E17K-AKT1 
mutation was detected in only 6 of 418 breast cancers (1.4%) confirming a role in 
breast cancer pathophysiology albeit in a limited number of breast cancers. 
Amplification of PDK1, PIK3CA, PIK3CB, AKT1, AKT2, and p70S6K are also 
among the extensive list of known aberrations that can activate PI3K signaling in 
 
cancer.1 The frequency of PI3K pathway mutational aberrations was markedly 
different among the different breast cancer subtypes, being most common in 
hormone receptor-positive tumors and least common in basal-like cancers.   
Consistent with a selective role for the PI3K pathway in hormone receptor-
positive tumors, PTEN protein expression was significantly lower in hormone 
receptor-positive than in other human breast tumors (Table 1). Consistent with 
this, when PI3K pathway activation status is estimated by AKT phosphorylation, 
the pathway is activated in up to 44% of hormone receptor-positive, 26% of 
HER2-positive and 16% of basal-like tumors.17,18 This breast cancer subtype 
specificity suggests that PIK3CA mutations and other PI3K pathway aberrations 
may play a distinct role in the pathogenesis of these different diseases. Further, 
since genomic aberrations can predict responsiveness to targeted therapies, and 
since multiple PI3K pathway members are frequently aberrant in human breast 
tumors through mutation and other anomalies, this creates an expectation that 
targeting this pathway will provide an effective therapeutic approach in breast 
cancer.1,3 Genomic aberrations such as those studied herein may facilitate 
identification of patients who will benefit from PI3K pathway-targeted therapies. 
 
PIK3CA and PTEN mutations have been reported to be mutually exclusive in 
many cancers with a notable exception being endometrial tumors.19,20 In the 
breast cancer cell lines and tumors analyzed herein, E17K-AKT1, PIK3CA, and 
PTEN mutations were also mutually exclusive.  
 
 
Using RPPA, which allows PTEN levels to be assessed as a continuous variable, 
PTEN protein levels were significantly lower in hormone receptor-positive 
cancers than in other human breast cancers.  Consistent with this, levels of AKT 
phosphorylation have been reported to be higher in hormone receptor positive 
tumors than in other breast cancer tumor lineages.17,18 Recent studies suggest 
that breast cancers in mice engineered to lack PTEN have characteristics most 
closely related to basal-like tumors 21. However, in humans, there does not 
appear to be an excess of basal-like tumors in women with Cowden’s syndrome 
which is caused by a germline mutation in PTEN (Charis Eng personal 
communication).22,23
 
PI3K pathway activation has been reported to be associated with poor outcomes 
in certain cancers.9 We have demonstrated that an integrated signature of PTEN 
protein loss and PIK3CA mutation in HER2-positive breast cancer is an even 
stronger predictor of trastuzumab resistance than either PIK3CA mutation or 
PTEN loss alone.9,10 Herein, PIK3CA mutations herein were not associated with 
a significant impact on hormone receptor-positive breast cancer patient outcome 
after adjuvant tamoxifen therapy, compatible with the results of a previous 
study.24 Another recent study found that, while PIK3CA mutation status overall 
was not prognostic, the presence of helical domain mutations predicted a poor 
outcome while the presence of kinase domain mutations predicted an improved 
outcome.25 However, unlike our study, this study was not confined to a 
homogeneously treated group of breast cancer patients with a specific subtype of 
 
breast cancer as described herein. Our study is the largest study to date of the 
outcome implications of PIK3CA pathway deregulation in a homogeneous group 
of patients with early stage hormone receptor-positive breast cancer treated only 
with adjuvant tamoxifen. In contrast, it has previously been reported that PTEN 
loss is associated with adverse outcomes in breast cancer.9,10,16  
 
Notwithstanding the lack of an outcome association with PIK3CA mutation status, 
there remains a high probability that appropriate PI3K pathway manipulation 
could alter outcomes for hormone receptor-positive breast cancer patients in 
response to hormonal manipulation or chemotherapy. However, a phase 3 trial of 
an mTor inhibitor in combination with an aromatase inhibitor failed to 
demonstrate significant activity in an unselected hormone receptor-positive 
breast cancer patient population. 26 Whether mTor represents a suboptimal target 
for therapy in breast cancer, whether other combinations of therapies with mTor 
inhibition will be effective or whether feedback loops bypass the activity of mTor 
inhibitors requires additional analysis.27 Novel PI3K- and AKT-targeted therapies 
are being introduced into trials (e.g. perifosine (Keryx), SF1126 (Semafore), 
PX166 (Prolx), BEZ256 (Novartis), EX147 (Exelixis)) with the expectation that 
these compounds may bypass feedback loops and have more efficacy than mTor 
inhibitors. It is clear that a comprehensive understanding of kinase signaling 
interconnections is important for the rational implementation of drugs and 
particularly drug combinations targeting the PI3K pathway in breast cancers with 
different genomic aberrations targeting this pathway.  
 
 Unlike E17K-AKT1 mutations that were not detected in 41 cell lines, PIK3CA and 
PTEN mutations were more common in cell lines than patient tumors (Table 1). A 
higher frequency of PIK3CA and PTEN mutations could be due to a failure to 
detect mutations in tumors as a result of technical factors. However, this alone is 
unlikely to account for these differences since AKT1 mutations should then be 
more readily identified in cell lines. Thus, there is likely to be a selection pressure 
for PIK3CA and PTEN but not E17K-AKT1 mutations during adaptation to 
culture. Due to the low frequency of aberrations and the generally good outcome 
associated with hormone receptor-positive cancers, determining whether E17K-
AKT1 mutations contribute to patient outcomes and therapy responsiveness 
requires analysis of a large number of tumors. However, none of the six patients 
with E17K-AKT1 mutant hormone receptor-positive tumors in this study have 
recurred, suggesting that AKT1 mutation may be associated with a good 
outcome. If confirmed in a larger series, this may indicate that AKT activation 
confers a selective advantage during early hormone receptor-positive 
tumorigenesis but inhibits tumor dissemination during progression. Consistent 
with this, while AKT1 is necessary for optimal initiation of tumorigenesis, its 
expression actually inhibits invasion and metastasis.28-30 AKT may thus be an 
initiating oncogene for hormone receptor-positive breast cancers but its anti-
invasive properties may prevent disease progression contributing to a good 
prognosis. As demonstrated herein, PTEN protein loss and PIK3CA mutations 
have markedly different functional effects on signaling through the PI3K pathway 
 
in hormone receptor-positive breast cancers and in breast cancer cell lines, likely 
leading to the demonstrated differential sensitivity to the pathway inhibitor 
LY294002. Thus, PI3K pathway activation by PTEN loss versus PIK3CA 
mutation could lead to different outcomes and is likely to have important 
implications for the use of pathway-targeted therapies in human tumors. 
 
In summary, PI3K pathway aberrations are common in breast cancer pointing to 
an important role for this signaling pathway in breast carcinogenesis and as a 
potential target for therapy. The clear breast cancer subtype specificity of these 
aberrations suggests that they may play a distinct role in the pathogenesis of 
different breast cancer subtypes. PI3K pathway mutational aberrations and low 
PTEN protein expression are particularly prominent in hormone receptor-positive 
breast cancer. Despite the lack of an outcome association with common PIK3CA 
mutations, these mutations may have important implications for the clinical 
selection of targeted therapies in patients with hormone receptor-positive tumors 
that possess these aberrations.
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Figure 1. Detection of PIK3CA and AKT1 mutations. A mass spectrometry 
tracing of an AKT1 E17K mutant SNP allele in a hormone receptor-positive 
breast cancer. 
 
Figure 2. Effect of PTEN loss and PIK3CA mutation on AKT activation in 
hormone receptor-positive human breast tumors. PTEN and the two AKT 
phosphorylation sites (AKTp308, AKTp473) were quantified in hormone receptor-
positive breast cancers using reverse phase protein lysate array. The 
quantification data were then log transformed (base 2), mean centered, ordered 
by increasing PTEN expression level from above down and plotted in the heat 
map shown. In the mean centering schema used, red indicates a relatively high 
level of (phospho)protein expression and green a relatively low level of 
(phospho)protein expression. The level of PTEN expression is shown in lane 1 
and the levels of AKT phosphorylation at threonine 308 (lane 2) and serine 473 
(lane 3) are shown in lanes 2 and 3, respectively. Clearly, AKT phosphorylation is 
strongly inversely correlated with PTEN protein expression. However, there is no 
clear association between PIK3CA mutation and AKT phosphorylation at either 
amino acid site. Further, there was no significant difference (p=0.41) in the 
frequency of tumors with PIK3CA mutations among those tumors with the highest 
and lowest quartiles of PTEN expression (17/77 (22.1%) and 12/77 (15.6%), 
respectively).Only tumors from the largest single institution batch (i.e. from Clinic 
Hospital) were used for this analysis.    
 
 
Figure 3. Effect of PTEN and PIK3CA mutations on AKT activation/ 
phosphorylation at serine 473 in 40 breast cancer cell lines. AKT 
phosphorylation at serine 473 (AKTp473) was significantly higher in PTEN 
mutant cell lines than in PIK3CA-mutant (p=0.004) or PTEN/PIK3CA-wild type 
(p=0.0002) cell lines. In contrast, there was no significant difference (p=0.49) in 
AKT phosphorylation at serine 473 between PIK3CA-mutant and PTEN/PIK3CA-
wild type cell lines. AKTp473 was quantified using reverse phase protein array 
and expressed on the Y axis after logarithmic conversion and mean centering. 
 
Figure 4. The relative sensitivity of 12 hormone receptor-positive breast 
cancer cell lines to the PI3K inhibitor LY294002. LY294002 was applied to the 
panel of hormone receptor positive-breast cancer cell lines and the concentration 
causing 50% growth inhibition (GI50) determined and presented as relative 
sensitivity (-Log GI50). The cell lines are presented in order of increasing PTEN 
protein expression (Lane A) as determined using reverse phase protein array 
(RPPA). PTEN-low (p=0.0065) and PTEN-mutant (p=0.02) cell lines are 
significantly more sensitive to growth inhibition by LY294002 than PIK3CA-
mutant cell lines. Lane B-AKT phosphorylation at Serine 473 determined using 
RPPA (color coded as in lane A i.e. green low, black mean and red high AKT 
phosphorylation); Lane C-cell line mutation status. 
 
Figure 5. Correlations between PIK3CA mutations and patient survival. 
 
No significant differences in recurrence-free (RFS (A, B)) or overall survival (OS 
(C, D)) times were found between patients with early stage PIK3CA-wild type 
hormone receptor-positive breast tumors and those with PIK3CA-mutant breast 
tumors after adjuvant tamoxifen therapy. 
 
Table 1. Frequency of mutations in the PIK3CA, AKT1 and PTEN genes 
along with PTEN protein expression in human breast cancers and breast 
cancer cell lines. PTEN protein expression was determined by reverse 
phase protein array independently for tumors and cell lines and is 
presented as mean centered log2 arbitrary units for comparison between 
breast cancer subgroups.  
^ Resequencing courtesy of Len Pennacchio and Jan-Fang Cheng of 
Lawrence Berkeley National Laboratory in breast cancers and by 
literature/internet (e.g. www.sanger.ac.uk) search in cell lines.  
^^ DNA extraction in these tumors courtesy of Mandy Madiredjo at NKI. 
* Catalytic domain PIK3CA mutations include H1047R, H1047L, H1047Y and 
G1049R in order of frequency. 
** Other PIK3CA mutations include E545K, E542K, N345K, E418K and 
P539R in order of frequency. 
*** Two distinct PIK3CA mutations were found together in four patients with 
HR+ breast cancer. 
**** One TN breast cancer cell line (BT20) had both a catalytic domain 
H1047R and non catalytic domain P539R mutation in PIK3CA. 
 
 Supplemental Table 1. Breast cancer cell lines and their estrogen receptor 
status, clinical subtype and PIK3CA/PTEN mutational status. 
 
Supplemental Table 2. Associations between clinical variables and PIK3CA 
mutation status in 166 early stage hormone receptor-positive breast 
cancers. In some categories, numbers may not add up to 166 due to missing 
data. 
 
Supplemental Table 3. Associations between PIK3CA mutation status and 
outcomes in 166 early stage hormone receptor-positive breast cancer 
patients treated only with adjuvant tamoxifen.  
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Table 1. Frequency of mutations in the PIK3CA, AKT1 and PTEN genes 
along with PTEN protein expression in human breast cancers and breast 
cancer cell lines. PTEN protein expression was determined by reverse 
phase protein array independently for tumors and cell lines and is 
presented as mean centered log2 arbitrary units for comparison between 
breast cancer subgroups.  
 
Mutation 
Tumor 
subtype 
PIK3CA 
catalytic 
domain* 
PIK3CA 
other** 
PIK3CA 
total 
PTEN^ AKT1 
E17K 
 
PTEN protein 
expression 
(mean +/- SD) 
All human 
breast 
tumors 
73/547 
(13.3%) 
44/547 
(8.0%) 
117/547 
(21.4%) 
2/88 
(2.3%) 
6/418 
(1.4%) 
Mean centered 
log2 expression 
(ANOVA p < 
0.0001): 
Human breast 
HR+*** 
49/240 
(20.4%) 
32/240 
(13.3%) 
81/240 
(33.8%) 
2/58 
(3.4%) 
6/240 
(2.5%) 
-0.25 (+/- 1.19) 
                   
ER+PR+ 
39/190 
(20.5%) 
22/190 
(11.6%) 
61/190 
(32.1%) 
1/48 
(2.1%) 
6/190 
(3.2%) 
- 
 
                   
ER+PR- 
10/45 
(22.2%) 
10/45 
(22.2%) 
20/45 
(44.4%) 
1/8 
(12.5%) 
0/45 
(0%) 
- 
                   ER-
PR+ 
0/5 (0%) 0/5 (0%) 0/5 (0%) 0/2 (0%) 0/5 (0%) - 
 
Human breast 
HER2+^^ 
12/65 
(18.5%) 
4/65 
(6.2%) 
16/65 
(24.6%) 
0/10 
(0%) 
0/65 
(0%) 
+0.58 (+/- 0.72) 
Human breast  
TN 
12/242 
(5.0%) 
8/242 
(3.3%) 
20/242 
(8.3%) 
0/20 
(0%) 
0/113 
(0%) 
+0.51 (+/- 0.82) 
All breast 
cancer cell 
lines 
7/41 
(17.1%) 
9/41 
(22%) 
16/41 
(39%) 
8/41 
(20%) 
0/41 
(0%) 
Mean centered 
log2 expression 
(ANOVA p = 
0.36): 
Breast cancer 
cell lines HR+ 
1/12 
(8.3%) 
3/12 
(25%) 
4/12 
(33.3%) 
5/12 
(41.7%)
0/12 
(0%) 
+0.16 (+/- 1.33) 
Breast cancer 
cell lines 
HER2+ 
2/10 
(20%) 
4/10 
(40%) 
6/10 
(60%) 
0/10 
(0%) 
0/10 
(0%) 
+0.40 (+/- 0.64) 
Breast cancer 
cell lines 
TN**** 
4/19 
(21%) 
2/19 
(10.5%) 
6/19 
(31.6%) 
3/19 
(15.8%)
0/19 
(0%) 
-0.28 (+/- 1.27) 
ER-estrogen receptor alpha; PR-progesterone receptor; HR-hormone 
receptor; HER2-human epidermal receptor 2; TN-triple negative; SD-standard 
deviation. 
 
^ Resequencing courtesy of Len Pennacchio and Jan-Fang Cheng of 
Lawrence Berkeley National Laboratory in breast cancers and by 
literature/internet (e.g. www.sanger.ac.uk) search in cell lines.  
 
^^ DNA extraction in these tumors courtesy of Mandy Madiredjo at NKI. 
* Catalytic domain PIK3CA mutations include H1047R, H1047L, H1047Y and 
G1049R in order of frequency. 
** Other PIK3CA mutations include E545K, E542K, N345K, E418K and 
P539R in order of frequency. 
*** Two distinct PIK3CA mutations were found together in four patients with 
HR+ breast cancer. 
**** One TN breast cancer cell line (BT20) had both a catalytic domain 
H1047R and non catalytic domain P539R mutation in PIK3CA. 
 
 
Supplemental Table 1. Breast cancer cell lines and their estrogen receptor 
status, clinical subtype and PIK3CA/PTEN mutational status. 
Breast Cancer Cell 
line 
Estrogen receptor 
status 
Clinical Subtype Mutation 
MCF7 Positive Hormone receptor + PIK3CA E545K 
T47D Positive Hormone receptor + PIK3CA H1047R 
BT483 Positive Hormone receptor + PIK3CA E542K 
ZR751 Positive Hormone receptor + PTEN 
ZR75b Positive Hormone receptor + PTEN 
ZR7530 Positive Hormone receptor +  
MDAMB134v1 Positive Hormone receptor +  
MDAMB415 Positive Hormone receptor + PTEN 
CAMA1 Positive Hormone receptor + PTEN 
LY2 Positive Hormone receptor + PIK3CA E545K 
600MPE Positive Hormone receptor +  
HCC70 Positive Hormone receptor + PTEN 
BT474 Positive HER2-positive PIK3CA K111N 
HCC1569 Negative HER2-positive  
MDAMB361 Positive HER2-positive PIK3CA E545K 
MDAMB453 Negative HER2-positive PIK3CA H1047R 
SKBR3 Negative HER2-positive  
AU565 Negative HER2-positive  
SUM225 Negative HER2-positive  
HCC202 Negative HER2-positive PIK3CA E545K 
UACC812 Positive HER2-positive PIK3CA N345K 
UACC893 Positive HER2-positive PIK3CA H1047R 
MDAMB468 Negative Triple negative PTEN 
HBL100 Negative Triple negative  
HCC38 Negative Triple negative  
HCC1187 Negative Triple negative  
HCC1954 Negative Triple negative PIK3CA H1047R 
HCC2185 Negative Triple negative PIK3CA E545K 
MDAMB231 Negative Triple negative  
BT20 Negative Triple negative PIK3CA 
H1047R/P539R 
BT549 Negative Triple negative PTEN 
MDAMB157 Negative Triple negative PTEN 
HS578T Negative Triple negative  
HCC1500 Negative Triple negative  
HCC3153 Negative Triple negative  
MCF10A Negative Triple negative  
MCF10F Negative Triple negative  
MCF12A Negative Triple negative  
 
SUM149PT Negative Triple negative  
SUM159PT  Triple negative PIK3CA H1047L 
SUM185PE Negative Triple negative PIK3CA H1047R 
 
Supplemental Table 2. Associations between clinical variables and PIK3CA 
mutation status in 166 early stage hormone receptor-positive breast 
cancers.  
 
 All Tumors PIK3CA Wild Type PIK3CA Mutation  
 N Percent N Percent N Percent P-Value 
N 166  109  57   
Histology        
Other 36 21.7 28 25.7 8 14.0  
Ductal 130 78.3 81 74.3 49 86.0 0.112 
Pathologic T        
T1 59 35.5 42 38.5 17 29.8  
T2 81 48.8 48 44.0 33 57.9  
T3/4 26 15.7 19 17.4 7 12.3 0.308 
Pathologic N        
N0 106 63.9 75 68.8 31 54.4  
N1-N3 60 36.1 34 31.2 26 45.6 0.089 
ER        
Negative 3 1.8 3 2.8 0 0.0  
Positive 163 98.2 106 97.2 57 100.0 0.320 
PR        
Negative 36 21.7 19 17.4 17 29.8  
Positive 130 78.3 90 82.6 40 70.2 0.076 
Summary stage        
I 47 28.5 35 32.4 12 21.1  
II 95 57.6 56 51.9 39 68.4  
III 23 13.9 17 15.7 6 10.5 0.148 
Nuclear Grade        
I 43 41.3 29 39.7 14 45.2  
II 49 47.1 37 50.7 12 38.7  
III 12 11.5 7 9.6 5 16.1 0.666 
 
* In some categories, numbers may not add up to 166 due to missing data.
 
Supplemental Table 3. Associations between PIK3CA mutation status and outcomes in 166 early stage hormone 
receptor-positive breast cancer patients treated only with adjuvant tamoxifen.  
Overall survival: N 
N 
Events 
3 Year 
Estimate 95% C.I. 
4 Year 
Estimate 95% C.I. 
5 Year 
Estimate 95% C.I P-Value 
All 166 45 88.9% (83.8%, 94%) 84% 
(77.8%, 
90.2%) 82.3% 
(75.9%, 
88.8%)  
PIK3CA          
Wild Type 109 30 88.5% (82%, 94.9%) 82.2% 
(74.2%, 
90.2%) 80.9% 
(72.6%, 
89.2%)  
Mutation 57 15 89.8% 
(81.4%, 
98.3%) 87.5% 
(78.2%, 
96.9%) 85.1% 
(74.8%, 
95.3%) 0.620 
PIK3CA          
Wild Type 109 30 88.5% (82%, 94.9%) 82.2% 
(74.2%, 
90.2%) 80.9% 
(72.6%, 
89.2%)  
Catalytic 36 10 87.1% 
(75.3%, 
98.9%) 83.5% 
(70.2%, 
96.8%) 79.5% 
(64.7%, 
94.3%)  
Other 21 5 94.4% 
(83.9%, 
100.0%) 94.4% 
(83.9%, 
100.0%) 94.4% 
(83.9%, 
100.0%) 0.710 
Recurrence-free survival:          
All 166 41 88.9% 
(83.7%, 
94.1%) 88.1% 
(82.7%, 
93.4%) 85.4% 
(79.4%, 
91.4%)  
PIK3CA          
Wild Type 109 26 88.5% 
(82.1%, 
94.9%) 87.2% (80.4%, 94%) 85.8% 
(78.6%, 
93.1%)  
Mutation 57 15 89.5% 
(80.9%, 
98.2%) 89.5% 
(80.9%, 
98.2%) 84.4% 
(73.7%, 
95.1%) 0.944 
PIK3CA          
Wild Type 109 26 88.5% 
(82.1%, 
94.9%) 87.2% (80.4%, 94%) 85.8% 
(78.6%, 
93.1%)  
Catalytic 36 10 83.9% 
(70.9%, 
96.9%) 83.9% 
(70.9%, 
96.9%) 83.9% 
(70.9%, 
96.9%)  
Other 21 5 100.0%  100.0%  86.7% 
(69.5%, 
100%) 0.711 
 
